Product Code: HIT 9441
The nuclear medicine software market was valued at USD 970.03 million in 2025 and is estimated to reach USD 1,491.6 million by 2030, registering a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine software market is being influenced by a convergence of clinical and technological advancements, along with favorable regulatory and reimbursement frameworks in developed and developing nations. These technological advancements are significantly transforming how nuclear medicine imaging and radiopharmaceutical therapies are delivered.
Scope of the Report |
Years Considered for the Study | 2023-2030 |
Base Year | 2024 |
Forecast Period | 2025-2030 |
Units Considered | Value (USD million) |
Segments | Software Type, Workflow, Integration Complexity, Software Licensing Model, Revenue Model, Application, Therapeutic Area, Technology Maturity, End User, and Region |
Regions covered | North America, Europe, Asia Pacific, Middle East & Africa, and Latin America |
Key factors driving growth include the increasing demand for accurate image analysis, PACS integration, dosimetry, treatment planning, advanced analytics, and reporting. In addition to the growing demand in the diagnostic imaging segment, nuclear medicine therapeutic applications are seeing an increase in the adoption rates of theranostics. Leading market players are increasingly integrating their solutions with AI-powered tools for tumor segmentation and automated reporting, thereby enhancing diagnostic accuracy and workflow efficiency. The pharmaceutical and life sciences sectors are fueling the demand for advanced nuclear medicine software solutions due to the expanding pipeline of radiopharmaceuticals. Furthermore, the growing transition towards cloud-native PACS integration and remotely accessible solutions is promoting the development of advanced software solutions. However, the growth of this market is moderately restrained due to challenges arising from data security, inadequate infrastructure, and radiation exposure.

"Cloud-native platforms are expected to register the fastest growth over the forecast period."
The lucrative growth of cloud-native platforms is attributed to the increasing demand for remote access, interoperability, and scalability across healthcare systems. Nuclear medicine is rapidly evolving through multi-center collaborations and AI-powered analytics, driving the need for cloud-native solutions. These platforms enable real-time data sharing, faster software updates, and enhanced cybersecurity features. Furthermore, healthcare systems are transitioning towards a value-based care approach, in which cloud-developed infrastructure supports integrated decision-making, thereby enhancing overall patient care. Moreover, the adoption of advanced nuclear medicine workflows requires cloud-based software platforms that can synchronize imaging and treatment planning. Some companies offering cloud-native platforms include Sectra's Cloud Imaging Platform and Intelerad's IntelePACS Cloud. These solutions support PET/SPECT viewing and reporting, seamlessly integrating with AI modules for remote accessibility.
"The subscription-based/Software-as-a-service (SaaS) models segment held the largest share of the nuclear medicine software market in 2024."
The subscription-based Software-as-a-Service (SaaS) model segment dominates the software licensing segment in the nuclear medicine software market in 2024. This dominance is due to the lower upfront costs, flexibility, and cloud-based deployments offered by this model. Healthcare providers, life sciences companies, and research institutes are increasingly shifting from traditional perpetual licensing models because of the high capital expenditures and limited scalability associated with them. SaaS models provide regular software updates with predictable operational costs and seamlessly integrate with cloud-native PACS and radiology systems, thereby supporting hospitals and imaging centers in modernizing their nuclear imaging workflows. With the expansion of multi-site imaging networks, SaaS platforms enable centralized data access, interoperable workflows, and remote access diagnostics. Some of the leading market players offering their solutions through subscription-based SaaS models are GE Healthcare and Siemens Healthineers.
"North America market accounts for the largest share in the nuclear medicine software market in 2024."
The North American market dominated the nuclear medicine software sector in 2024, due to its advanced healthcare infrastructure, increasing adoption of hybrid imaging systems, and strong regulatory support for radiopharmaceutical-based diagnostics and therapeutics. Additionally, the significant presence of market leaders such as GE Healthcare and Siemens Healthineers contributes to the growth of the North American market. In contrast, the Asia Pacific market is expected to register the fastest growth rate over the forecast period. This growth is attributed to rising public and private investments in precision medicine, an escalating disease burden from cancer and cardiovascular diseases, and advancements in infrastructure across China, India, Japan, Australia, and South Korea. Furthermore, the region is experiencing rapid adoption of personalized dosimetry and theranostics, alongside increasing partnerships between local hospitals and globally established companies. Growing patient awareness, rising healthcare IT expenditure, and the increasing adoption of AI-based imaging solutions are further boosting growth in the Asia Pacific market.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine software marketplace.
The breakdown of primary participants is as mentioned below:
- By Company Type - Tier 1 (31%), Tier 2 (31%), and Tier 3 (28%)
- By Designation - C-level Executives (44%), Director-level (31%), and Managers (25%)
- By Region - North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), and Middle East & Africa (3%)
Key Players in the Nuclear Medicine Software Market
Prominent players in the nuclear medicine software market include include GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG(Germay), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Brainlab AG(Germany), Mirada Medical(UK), DOSIsoft SA(France), Bracco Group (Italy), Hermes Medical Solutions (Sweden), INVIA, LLC (US), Mediso Ltd. (Hungary), Canon Medical Systems Corporation (Japan), LabLogic Systems Ltd. (UK), Mirion Technologies (ec2 Software Solutions)(US), COMECER S.p.A.(Italy), RaySearch Laboratories(Sweden), UltraSPECT Inc. (US), Sectra AB (Sweden), Agfa-Gevaert Group (Belgium), Perceptive(UK).
Players adopted both organic and inorganic growth strategies, including product launches and enhancements, as well as investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances. These strategies aimed to increase their offerings, meet the unmet needs of customers, boost profitability, and expand their presence globally market.
The study includes an in-depth competitive analysis of these key players in the nuclear medicine software market, with their company profiles, recent developments, and key market strategies.
Research Coverage
- The report studies the nuclear medicine software market based on software type, workflow, integration complexity, software licensing model, revenue model, application, therapeutic area, technology maturity, end user, and region.
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
- The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
- The report studies micromarkets with respect to their growth trends, prospects, and contributions to the total nuclear medicine software market.
- The report forecasts the revenue of market segments with respect to five major regions.
Reasons to Buy the Report
The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.
This report provides insights into the following pointers:
- Analysis of key drivers (increasing demand for early and accurate diagnostics, growing focus on personalized medicine, integration of automated dosimetry tools, growing prevalence of chronic diseases and subsequent increase in clinical trials, effective monitoring of nuclear medicine software), restraints (high cost of imaging equipment, data privacy and security concerns, shortage of skilled professionals, interpolability issues), opportunities (infrastructure development, increased healthcare IT expenditure, data privacy and regulatory reforms), and challenges (compliance requirements, low penetration of advanced imaging devices, underdeveloped radiopharmcy ecosysytem, economic and financial barriers) influencing the industry macrodynamics of nuclear medicine software market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine software market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine software across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine software market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine software market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
- 1.3.2 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 LIMITATIONS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH APPROACH
- 2.1.1 SECONDARY RESEARCH
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY RESEARCH
- 2.1.2.1 Primary sources
- 2.1.2.2 Key data from primary sources
- 2.1.2.3 Breakdown of primaries
- 2.1.2.4 Insights from primary experts
- 2.2 RESEARCH METHODOLOGY DESIGN
- 2.3 MARKET SIZE ESTIMATION
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 MARKET SHARE ESTIMATION
- 2.6 STUDY ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
- 2.7.1 METHODOLOGY-RELATED LIMITATIONS
- 2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 OVERVIEW OF NUCLEAR MEDICINE SOFTWARE MARKET
- 4.2 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY & INTEGRATION COMPLEXITY
- 4.3 GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE SOFTWARE MARKET
- 4.4 NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL MIX
- 4.5 NUCLEAR MEDICINE SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Rising global disease prevalence
- 5.2.1.2 Surge in AI-powered theranostics
- 5.2.1.3 Adoption of cloud-based platforms & mobile/remote diagnostics
- 5.2.1.4 Radiopharmaceutical supply chain visibility & radiopharmaceutical software
- 5.2.1.5 Expansion of personalized medicine in nuclear applications
- 5.2.2 RESTRAINTS
- 5.2.2.1 High acquisition & total cost of ownership
- 5.2.2.2 Regulatory & approval delays with AI integration
- 5.2.2.3 Integration & interoperability challenges
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Precision & predictive dosimetry
- 5.2.3.2 Expansion of tele-nuclear medicine networks & mobile access
- 5.2.4 CHALLENGES
- 5.2.4.1 Lack of technical expertise
- 5.2.4.2 Regulatory uncertainties
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.4 INDUSTRY TRENDS
- 5.4.1 OVERVIEW OF USE CASES
- 5.4.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND ADVANCED ANALYTICS
- 5.4.3 SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SOLUTIONS
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 TECHNOLOGY ANALYSIS
- 5.7.1 KEY TECHNOLOGIES
- 5.7.1.1 SPECT/PET image reconstruction algorithms
- 5.7.1.2 Quantitative molecular imaging tools
- 5.7.1.3 Radiopharmaceutical dosimetry software
- 5.7.1.4 Artificial intelligence and machine learning
- 5.7.1.5 Multi-modality fusion & co-registration engines
- 5.7.2 COMPLEMENTARY TECHNOLOGIES
- 5.7.2.1 DICOM AND HL7 integration engines
- 5.7.2.2 Theranostics workflow orchestration tools
- 5.7.2.3 Cloud-based PACS/archiving solutions
- 5.7.3 ADJACENT TECHNOLOGIES
- 5.7.3.1 Molecular imaging-omics integration tools
- 5.7.3.2 Blockchain
- 5.8 REGULATORY ANALYSIS
- 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.8.2 REGULATORY ANALYSIS
- 5.9 PRICING ANALYSIS
- 5.9.1 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024)
- 5.9.2 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024)
- 5.9.3 PRICING MODELS (QUALITATIVE)
- 5.10 PORTER'S FIVE FORCES ANALYSIS
- 5.10.1 THREAT OF NEW ENTRANTS
- 5.10.2 THREAT OF SUBSTITUTES
- 5.10.3 BARGAINING POWER OF BUYERS
- 5.10.4 BARGAINING POWER OF SUPPLIERS
- 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.11 PATENT ANALYSIS
- 5.11.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS
- 5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.12.2 BUYING CRITERIA
- 5.13 END-USER ANALYSIS
- 5.13.1 UNMET NEEDS
- 5.13.2 END-USER EXPECTATIONS
- 5.14 KEY CONFERENCES & EVENTS, 2025-2026
- 5.14.1 NUCLEAR MEDICINE SOFTWARE MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2025-2026
- 5.15 CASE STUDY ANALYSIS
- 5.15.1 ENSURING PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY
- 5.15.1.1 Case 1: Strengthening quality control and patient outcomes with ANSTO's coordinated CRM program
- 5.15.2 STREAMLINING MULTI-MODALITY IMAGE FUSION FOR BETTER DIAGNOSTICS
- 5.15.2.1 Case 2: GE HealthCare's Xeleris platform enhances multi-modality imaging at a leading academic medical center
- 5.15.3 SUPPORTING REMOTE CONSULTATIONS WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS
- 5.15.3.1 Case 3: Sectra's cloud-based solution empowers remote nuclear medicine consultations for regional hospitals
- 5.16 INVESTMENT & FUNDING SCENARIO
- 5.17 BUSINESS MODEL ANALYSIS
- 5.17.1 LICENSE-BASED BUSINESS MODELS
- 5.17.2 SUBSCRIPTION-BASED BUSINESS MODELS
- 5.17.3 SOFTWARE-AS-A-SERVICE (SAAS) BUSINESS MODELS
- 5.17.4 PAY-PER-USE BUSINESS MODELS
- 5.17.5 FREEMIUM BUSINESS MODELS
- 5.17.6 INTEGRATED SERVICE AND SOFTWARE BUNDLE BUSINESS MODELS
- 5.18 IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE SOFTWARE MARKET
- 5.18.1 KEY USE CASES
- 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
- 5.18.2.1 Case study 1: AI-based low-dose PET image reconstruction
- 5.18.2.2 Case study 2: Dose-aware diffusion models for 3D low-dose PET
- 5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
- 5.18.3.1 Medical image analysis software
- 5.18.3.2 Radiology information systems
- 5.18.3.3 Clinical decision support systems
- 5.18.4 USER READINESS & IMPACT ASSESSMENT
- 5.18.4.1 User readiness
- 5.18.4.1.1 User A: Healthcare providers
- 5.18.4.1.2 User B: Pharmaceutical & biotechnology companies
- 5.18.4.2 Impact assessment
- 5.18.4.2.1 User A: Healthcare providers
- 5.18.4.2.1.1 Implementation
- 5.18.4.2.1.2 Impact
- 5.18.4.2.2 User B: Pharmaceutical & biotechnology companies
- 5.18.4.2.2.1 Implementation
- 5.18.4.2.2.2 Impact
- 5.19 IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE SOFTWARE MARKET
- 5.19.1 INTRODUCTION
- 5.19.2 KEY TARIFF RATES
- 5.19.3 PRICE IMPACT ANALYSIS
- 5.19.4 IMPACT ON COUNTRY/REGION
- 5.19.4.1 US
- 5.19.4.2 Europe
- 5.19.4.3 Asia Pacific
- 5.19.5 IMPACT ON END-USE INDUSTRIES
6 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE
- 6.1 INTRODUCTION
- 6.2 IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE
- 6.2.1 ABILITY TO OPTIMIZE NUCLEAR IMAGING THROUGH AI-POWERED ACQUISITION AND RECONSTRUCTION SOFTWARE TO DRIVE MARKET
- 6.3 IMAGE ANALYSIS & QUANTIFICATION SOFTWARE
- 6.3.1 AI INNOVATION, WORKFLOW OPTIMIZATION, AND PERSONALIZED CARE TRENDS TO SUPPORT GROWTH
- 6.4 WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE
- 6.4.1 NEED FOR ADVANCING NUCLEAR MEDICINE THROUGH INTEGRATED WORKFLOW MANAGEMENT SOLUTIONS TO BOOST GROWTH
- 6.5 PACS INTEGRATION & DATA MANAGEMENT SOFTWARE
- 6.5.1 GROWING NEED FOR RADIOTRACER-AWARE ANALYTICS, COMPLIANCE, AND INTEROPERABILITY TO BOOST ADOPTION
- 6.6 REPORTING & DOCUMENTATION SOFTWARE
- 6.6.1 EXPANDING HEALTHCARE INVESTMENTS IN APAC AND MIDDLE EAST TO ACCELERATE ADOPTION OF REPORTING & DOCUMENTATION SOFTWARE
- 6.7 RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE
- 6.7.1 OPERATIONAL, CLINICAL, AND REGULATORY CATALYSTS TO DRIVE MARKET GROWTH
- 6.8 DOSIMETRY & TREATMENT PLANNING SOFTWARE
- 6.8.1 PRECISION IMAGING AND AI-DRIVEN WORKFLOWS TO ADVANCE DOSIMETRY & TREATMENT PLANNING
- 6.9 QUALITY CONTROL & ASSURANCE SOFTWARE
- 6.9.1 HYBRID-IMAGING QA NEEDS, DIGITAL AUDIT READINESS, AND EDGE-BASED AI FOR OFFLINE ENVIRONMENTS TO FUEL GROWTH
- 6.10 AI & ADVANCED ANALYTICS SOFTWARE
- 6.10.1 ABILITY OF INTEGRATED AI ECOSYSTEMS TO REDEFINE NUCLEAR IMAGING EFFICIENCY TO SUPPORT MARKET
- 6.11 MOBILE & REMOTE ACCESS SOFTWARE
- 6.11.1 GROWING POPULARITY OF PORTABLE AND POINT-OF-CARE SCANNERS TO DRIVE MARKET DEMAND
7 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW
- 7.1 INTRODUCTION
- 7.2 IMAGE ACQUISITION
- 7.2.1 ADVANCED INNOVATIONS TRANSFORMING IMAGE ACQUISITION INTO DYNAMIC, MULTI-FUNCTIONAL COMPONENTS TO DRIVE MARKET
- 7.3 DATA PROCESSING
- 7.3.1 OPTIMIZING CLINICAL INSIGHTS WITH INTELLIGENT DATA PROCESSING IN NUCLEAR MEDICINE WORKFLOWS TO SUPPORT GROWTH
- 7.4 REPORTING
- 7.4.1 PRECISION AND EFFICIENCY ASSOCIATED WITH AI-INTEGRATED REPORTING SOLUTIONS TO TRANSFORM MARKET
- 7.5 DATA MANAGEMENT
- 7.5.1 GROWING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO STREAMLINE IMAGING WORKFLOWS TO DRIVE GROWTH
8 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY
- 8.1 INTRODUCTION
- 8.2 STANDALONE SOLUTIONS
- 8.2.1 AVAILABILITY OF ROBUST STANDALONE SOLUTIONS TAILORED TO SPECIFIC IMAGING AND ANALYSIS NEEDS TO BOOST MARKET
- 8.3 INTEGRATED SOLUTIONS
- 8.3.1 ADVANTAGES SUCH AS REDUCED MANUAL STEPS AND IMPROVED DIAGNOSTIC ACCURACY TO DRIVE DEMAND
- 8.4 CLOUD-NATIVE PLATFORMS
- 8.4.1 ABILITY OF CLOUD-NATIVE PLATFORMS TO DRIVE SCALABLE AND CONNECTED IMAGING IN NUCLEAR MEDICINE TO DRIVE MARKET
9 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING
- 9.1 INTRODUCTION
- 9.2 PERPETUAL/TRADITIONAL LICENSES
- 9.2.1 GROWING DEMAND FOR PREDICTABLE LONG-TERM COSTS TO DRIVE ADOPTION
- 9.3 SUBSCRIPTION/SAAS LICENSES
- 9.3.1 ABILITY OF CLOUD-BASED SAAS SOLUTIONS TO ENHANCE IMAGING SCALABILITY AND EXPAND ACCESS TO FUEL GROWTH
- 9.4 USAGE-BASED LICENSES
- 9.4.1 ADVANTAGES SUCH AS SCALABLE ACCESS, REGULATORY COMPLIANCE, AND OPTIMIZED COSTS TO DRIVE DEMAND
- 9.5 ENTERPRISE AGREEMENTS
- 9.5.1 SEAMLESS DIGITAL TRANSFORMATION IN NUCLEAR MEDICINE THROUGH ENTERPRISE AGREEMENTS TO SUPPORT MARKET GROWTH
10 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL
- 10.1 INTRODUCTION
- 10.2 SOFTWARE LICENSES
- 10.2.1 ADVANTAGES SUCH AS SCALABLE, AI-POWERED, AND COMPLIANT IMAGING SOLUTIONS TO DRIVE DEMAND
- 10.3 MAINTENANCE & SUPPORT
- 10.3.1 RELIABLE DIAGNOSTICS AND MINIMIZED DOWNTIME ASSOCIATED WITH MAINTENANCE & SUPPORT SERVICES TO BOOST MARKET
- 10.4 PROFESSIONAL SERVICES
- 10.4.1 OPTIMIZING PHARMACY OPERATIONS THROUGH COMPREHENSIVE AUTOMATION SERVICES TO DRIVE GROWTH
- 10.5 CLOUD SERVICES
- 10.5.1 ACCELERATING NUCLEAR MEDICINE TRANSFORMATION THROUGH CLOUD-DRIVEN IMAGING AND AI INTEGRATION TO BOOST MARKET
11 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION
- 11.1 INTRODUCTION
- 11.2 DIAGNOSTICS
- 11.2.1 AUTOMATED IMAGE INTERPRETATION
- 11.2.1.1 Ability of AI-powered automated interpretation tools to streamline imaging workflows and reduce variability to boost adoption
- 11.2.2 TUMOR SEGMENTATION & QUANTIFICATION
- 11.2.2.1 Advancing precision oncology through AI-powered tumor segmentation solutions to support market growth
- 11.3 THERAPEUTICS
- 11.3.1 PREDICTIVE ANALYTICS
- 11.3.1.1 Advantages such as enhanced dosimetry accuracy and improved clinical outcomes to drive growth
- 11.3.2 WORKFLOW OPTIMIZATION & QUALITY CONTROL
- 11.3.2.1 Ability of workflow optimization and quality control solutions to enhance operational efficiency to boost market
- 11.3.3 PERSONALIZED DOSIMETRY CALCULATIONS
- 11.3.3.1 Optimized radiation delivery and standardized nuclear medicine workflows to drive demand
- 11.3.4 THERANOSTICS
- 11.3.4.1 Advantages such as real-time treatment optimization in nuclear medicine to drive popularity of theranostics
- 11.4 EMERGENCY & STAT WORKFLOWS
- 11.4.1 NEED TO ACCELERATE CRITICAL CARE DELIVERY WITH AI-DRIVEN NUCLEAR MEDICINE SOFTWARE SOLUTIONS TO PROPEL MARKET
- 11.5 CLINICAL RESEARCH
- 11.5.1 GROWING DEMAND FOR SCALABLE SERVICE SOLUTIONS THAT STREAMLINE IT DEPLOYMENT TO FURTHER MARKET GROWTH
12 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA
- 12.1 INTRODUCTION
- 12.2 ONCOLOGY
- 12.2.1 GROWING NEED FOR CANCER DETECTION AND THERAPY PLANNING THROUGH MOLECULAR IMAGING MODALITIES TO DRIVE GROWTH
- 12.3 NEUROLOGY
- 12.3.1 ADVANTAGES SUCH AS EARLY DETECTION, FUNCTIONAL BRAIN MAPPING, AND AUTOMATED DISEASE TRACKING TO DRIVE DEMAND
- 12.4 CARDIOLOGY
- 12.4.1 NEED TO TRANSFORM CARDIAC NUCLEAR IMAGING WITH SMART TECHNOLOGIES TO BOOST GROWTH
- 12.5 OTHER THERAPEUTIC AREAS
13 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY
- 13.1 INTRODUCTION
- 13.2 UPCOMING TECHNOLOGIES
- 13.2.1 AI & ADVANCED ANALYTICS
- 13.2.1.1 High burden of neurodegenerative diseases and oncology imaging complexity to boost market
- 13.2.2 DOSIMETRY & TREATMENT PLANNING
- 13.2.2.1 Rise of radioligand therapies like lutetium-177 to increase dosimetry software adoption
- 13.2.3 CLOUD-NATIVE PLATFORMS
- 13.2.3.1 Scalable AI-integrated nuclear medicine solutions with remote accessibility to drive nuclear medicine software growth
- 13.2.4 MOBILE & REMOTE ACCESS
- 13.2.4.1 Growing use of portable imaging devices, hybrid care demands, and supportive reimbursement trends to support market growth
- 13.3 MATURE TECHNOLOGIES
- 13.3.1 IMAGE ACQUISITION & RECONSTRUCTION
- 13.3.1.1 Ability of image reconstruction to drive precision and low-dose imaging in nuclear medicine to boost market
- 13.3.2 PACS INTEGRATION
- 13.3.2.1 Rise of hybrid imaging, need for SUV harmonization, and increasing regulatory focus on dosimetry to propel market
- 13.3.3 QUALITY CONTROL
- 13.3.3.1 Advancing quality control through standardized reconstruction in nuclear medicine to aid growth
14 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER
- 14.1 INTRODUCTION
- 14.2 HEALTHCARE PROVIDERS
- 14.2.1 HOSPITALS
- 14.2.1.1 Ability of hospitals to drive diagnostic precision and workflow efficiency in nuclear medicine to boost market
- 14.2.2 OUTPATIENT SETTINGS
- 14.2.2.1 Need for accessibility, efficiency, and growth in nuclear medicine software to boost adoption
- 14.2.3 DIAGNOSTIC & IMAGING CENTERS
- 14.2.3.1 Expanding access and precision in nuclear diagnostics to support market growth
- 14.2.4 RADIOPHARMACIES
- 14.2.4.1 Accelerating radiopharmaceutical precision and safety through radiopharmacy software innovations to fuel growth
- 14.2.5 OTHER HEALTHCARE PROVIDERS
- 14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 14.3.1 EXPANDING INFLUENCE OF NUCLEAR MEDICINE SOFTWARE IN RADIOPHARMACEUTICAL R&D AND CLINICAL TRIALS TO BOOST MARKET
- 14.4 MEDTECH COMPANIES
- 14.4.1 NEED TO ADVANCE NUCLEAR IMAGING TRIALS WITH PRECISION SOFTWARE INTEGRATION TO PROPEL MARKET
- 14.5 OTHER END USERS
15 NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION
- 15.1 INTRODUCTION
- 15.2 NORTH AMERICA
- 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 15.2.2 US
- 15.2.2.1 Emergence of hybrid imaging systems with enhanced diagnostic accuracy to drive market growth
- 15.2.3 CANADA
- 15.2.3.1 Government initiatives and funding to support market growth
- 15.3 EUROPE
- 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 15.3.2 GERMANY
- 15.3.2.1 Rising theranostic procedures to drive demand for advanced dosimetry and imaging software
- 15.3.3 UK
- 15.3.3.1 Infrastructure expansion and digital health initiatives to advance market growth
- 15.3.4 FRANCE
- 15.3.4.1 Accelerated digital transformation and expansion of targeted radiotherapy to drive growth
- 15.3.5 ITALY
- 15.3.5.1 Growing need for tailored diagnostics to drive nuclear medicine software market growth
- 15.3.6 SPAIN
- 15.3.6.1 Targeted public investments to drive advancements in nuclear medicine software
- 15.3.7 REST OF EUROPE
- 15.4 ASIA PACIFIC
- 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 15.4.2 JAPAN
- 15.4.2.1 Deeply ingrained culture of technological advancements in healthcare and medical imaging to support market
- 15.4.3 CHINA
- 15.4.3.1 China's strategy for healthcare modernization and technological independence to boost growth
- 15.4.4 INDIA
- 15.4.4.1 Steady growth in number of nuclear medicine facilities and SPECT/PET equipment to fuel growth
- 15.4.5 REST OF ASIA PACIFIC
- 15.5 LATIN AMERICA
- 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 15.5.2 BRAZIL
- 15.5.2.1 Improving healthcare infrastructure to boost procedural volume
- 15.5.3 MEXICO
- 15.5.3.1 Increasing focus on digital transformation within healthcare system to support market growth
- 15.5.4 REST OF LATIN AMERICA
- 15.6 MIDDLE EAST & AFRICA
- 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 15.6.2 GCC COUNTRIES
- 15.6.2.1 Substantial investments and national visions to transform market
- 15.6.3 REST OF MIDDLE EAST & AFRICA
16 COMPETITIVE LANDSCAPE
- 16.1 OVERVIEW
- 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET
- 16.3 REVENUE ANALYSIS, 2020-2024
- 16.4 MARKET SHARE ANALYSIS, 2024
- 16.4.1 GLOBAL MARKET SHARE ANALYSIS FOR PET (POSITRON EMISSION TOMOGRAPHY)
- 16.4.2 GLOBAL MARKET SHARE ANALYSIS FOR SPECT (SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY)
- 16.5 BRAND/PRODUCT COMPARISON
- 16.6 COMPANY VALUATION & FINANCIAL METRICS
- 16.6.1 FINANCIAL METRICS
- 16.6.2 COMPANY VALUATION
- 16.7 MARKET RANKING ANALYSIS
- 16.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 16.8.1 STARS
- 16.8.2 EMERGING LEADERS
- 16.8.3 PERVASIVE PLAYERS
- 16.8.4 PARTICIPANTS
- 16.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 16.8.5.1 Company footprint
- 16.8.5.2 Region footprint
- 16.8.5.3 Software type footprint
- 16.8.5.4 Workflow footprint
- 16.8.5.5 Integration complexity footprint
- 16.8.5.6 Application footprint
- 16.8.5.7 Therapeutic area footprint
- 16.8.5.8 End-user footprint
- 16.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 16.9.1 PROGRESSIVE COMPANIES
- 16.9.2 RESPONSIVE COMPANIES
- 16.9.3 DYNAMIC COMPANIES
- 16.9.4 STARTING BLOCKS
- 16.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 16.9.5.1 Detailed list of key startups/SMEs
- 16.9.5.2 Competitive benchmarking of startups/SMEs
- 16.10 COMPETITIVE SCENARIO
- 16.10.1 PRODUCT LAUNCHES & APPROVALS
- 16.10.2 DEALS
- 16.10.3 EXPANSIONS
- 16.10.4 OTHER DEVELOPMENTS
17 COMPANY PROFILES
- 17.1 KEY PLAYERS
- 17.1.1 GE HEALTHCARE
- 17.1.1.1 Business overview
- 17.1.1.2 Products & services offered
- 17.1.1.3 Recent developments
- 17.1.1.3.1 Product launches & approvals
- 17.1.1.3.2 Deals
- 17.1.1.3.3 Expansions
- 17.1.1.4 MnM view
- 17.1.1.4.1 Right to win
- 17.1.1.4.2 Strategic choices
- 17.1.1.4.3 Weaknesses & competitive threats
- 17.1.2 SIEMENS HEALTHINEERS AG
- 17.1.2.1 Business overview
- 17.1.2.2 Products & services offered
- 17.1.2.3 Recent developments
- 17.1.2.3.1 Product launches
- 17.1.2.3.2 Deals
- 17.1.2.4 MnM view
- 17.1.2.4.1 Right to win
- 17.1.2.4.2 Strategic choices
- 17.1.2.4.3 Weaknesses & competitive threats
- 17.1.3 KONINKLIJKE PHILIPS N.V.
- 17.1.3.1 Business overview
- 17.1.3.2 Products & services offered
- 17.1.3.3 Recent developments
- 17.1.3.3.1 Product launches
- 17.1.3.4 MnM view
- 17.1.3.4.1 Right to win
- 17.1.3.4.2 Strategic choices
- 17.1.3.4.3 Weaknesses & competitive threats
- 17.1.4 LANTHEUS
- 17.1.4.1 Business overview
- 17.1.4.2 Products & services offered
- 17.1.4.3 Recent developments
- 17.1.4.3.1 Deals
- 17.1.4.3.2 Other developments
- 17.1.4.4 MnM view
- 17.1.4.4.1 Right to win
- 17.1.4.4.2 Strategic choices
- 17.1.4.4.3 Weaknesses & competitive threats
- 17.1.5 CANON MEDICAL SYSTEMS CORPORATION
- 17.1.5.1 Business overview
- 17.1.5.2 Products & services offered
- 17.1.5.3 Recent developments
- 17.1.5.4 MnM view
- 17.1.5.4.1 Right to win
- 17.1.5.4.2 Strategic choices
- 17.1.5.4.3 Weaknesses & competitive threats
- 17.1.6 MIRION TECHNOLOGIES, INC.
- 17.1.6.1 Business overview
- 17.1.6.2 Products & services offered
- 17.1.6.3 Recent developments
- 17.1.6.3.1 Product launches
- 17.1.6.3.2 Deals
- 17.1.6.4 MnM view
- 17.1.6.4.1 Right to win
- 17.1.6.4.2 Strategic choices
- 17.1.6.4.3 Weaknesses & competitive threats
- 17.1.7 BRAINLAB AG
- 17.1.7.1 Business overview
- 17.1.7.2 Products & services offered
- 17.1.7.3 Recent developments
- 17.1.7.3.1 Product approvals
- 17.1.8 MIRADA MEDICAL LIMITED
- 17.1.8.1 Business overview
- 17.1.8.2 Products & services offered
- 17.1.8.3 Recent developments
- 17.1.8.3.1 Product approvals
- 17.1.8.3.2 Deals
- 17.1.9 DOSISOFT SA
- 17.1.9.1 Business overview
- 17.1.9.2 Products & services offered
- 17.1.9.3 Recent developments
- 17.1.9.3.1 Product approvals
- 17.1.9.3.2 Deals
- 17.1.10 BRACCO GROUP
- 17.1.10.1 Business overview
- 17.1.10.2 Products & services offered
- 17.1.10.3 Recent developments
- 17.1.10.3.1 Product launches & approvals
- 17.1.11 HERMES MEDICAL SOLUTIONS
- 17.1.11.1 Business overview
- 17.1.11.2 Products & services offered
- 17.1.11.3 Recent developments
- 17.1.11.3.1 Product launches & approvals
- 17.1.11.3.2 Deals
- 17.1.12 INVIA, LLC
- 17.1.12.1 Business overview
- 17.1.12.2 Products & services offered
- 17.1.12.3 Recent developments
- 17.1.12.3.1 Product launches
- 17.1.12.3.2 Deals
- 17.1.13 MEDISO LTD.
- 17.1.13.1 Business overview
- 17.1.13.2 Products & services offered
- 17.1.13.3 Recent developments
- 17.1.13.3.1 Product launches & approvals
- 17.1.14 LABLOGIC SYSTEMS LTD.
- 17.1.14.1 Business overview
- 17.1.14.2 Products & services offered
- 17.1.14.3 Recent developments
- 17.1.14.3.1 Product approvals
- 17.1.15 COMECER S.P.A. PRIVATE
- 17.1.15.1 Business overview
- 17.1.15.2 Products & services offered
- 17.1.15.3 Recent developments
- 17.1.15.3.1 Product updates
- 17.1.15.3.2 Deals
- 17.1.16 RAYSEARCH LABORATORIES
- 17.1.16.1 Business overview
- 17.1.16.2 Products & services offered
- 17.1.16.3 Recent developments
- 17.1.16.3.1 Product launches
- 17.1.17 ULTRASPECT INC.
- 17.1.17.1 Business overview
- 17.1.17.2 Products & services offered
- 17.1.18 SECTRA AB
- 17.1.18.1 Business overview
- 17.1.18.2 Products & services offered
- 17.1.18.3 Recent developments
- 17.1.18.3.1 Product launches
- 17.1.18.3.2 Deals
- 17.1.19 AGFA-GEVAERT GROUP
- 17.1.19.1 Business overview
- 17.1.19.2 Products & services offered
- 17.1.20 PERCEPTIVE
- 17.1.20.1 Business overview
- 17.1.20.2 Products & services offered
- 17.1.20.3 Recent developments
- 17.1.20.3.1 Product launches
- 17.1.20.3.2 Deals
- 17.2 OTHER PLAYERS
- 17.2.1 SYNTERMED INC.
- 17.2.2 SEGAMI CORPORATION
- 17.2.3 VERSANT MEDICAL PHYSICS & RADIATION SAFETY
- 17.2.4 PIXMEO
- 17.2.5 PAIRE
- 17.2.6 SUBTLE MEDICAL, INC.
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS